Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, A. Nascimento, Giacomo P. Comi et al.|The Lancet Neurology|2024Cited by 128
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular DystrophyAnne M. Connolly, Ewa Carrier, Craig M. Zaidman et al.|Journal of Neuromuscular Diseases|2023Cited by 24
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History ComparisonsCraig M. McDonald, Michela Guglieri, Dragana Vučinić et al.|Annals of Clinical and Translational Neurology|2025Cited by 12
Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trialAnne M. Connolly, Ewa Carrier, Brenda Wong et al.|medRxiv|2025Cited by 3
Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trialBrenda Wong, H. Phan, Yann Péréon et al.|medRxiv|2025Cited by 2